COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Proof of Concept Study of L-Alanyl-L-Glutamine for the Reduction of Peritoneal Adhesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04250467
Recruitment Status : Completed
First Posted : January 31, 2020
Last Update Posted : January 31, 2020
Information provided by (Responsible Party):
Temple Therapeutics BV

Brief Summary:
This study evaluates whether L-Alanyl-L-Glutamine can reduce the incidence, extent and severity of adhesions after myomectomy. Half of the participants will receive L-Alanyl-L-Glutamine and the other half of participants will receive a saline placebo at the time of myomectomy.

Condition or disease Intervention/treatment Phase
Adhesion; Peritoneum Drug: L-Alanyl/L-Glutamine Drug: Physiologic saline Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Proof of Concept Study of L-Alanyl-L-Glutamine for the Reduction of Peritoneal Adhesions in Adult Females Undergoing Myomectomy
Actual Study Start Date : February 15, 2015
Actual Primary Completion Date : October 20, 2016
Actual Study Completion Date : October 20, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Glutamine

Arm Intervention/treatment
Experimental: L-Alanyl-L-Glutamine
Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of myomectomy.
Drug: L-Alanyl/L-Glutamine
Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
Other Name: Evitar

Placebo Comparator: Placebo-Physiological Saline
Participants receiving intraperitoneal administration of physiological saline at the time of myomectomy.
Drug: Physiologic saline
Other Name: Placebo

Primary Outcome Measures :
  1. Efficacy of L-Alanyl-L-Glutamine [ Time Frame: 6-8 weeks ]
    A statistically significant reduction in the incidence, extent and severity of adhesions observed in the L-Alanyl-L-Glutamine treated group compared to the saline control group using the American Fertility Society grading system.

Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by clinical blood work abnormalities and physical examination. [ Time Frame: 8 weeks ]
    Adverse events, adverse drug reactions and clinical laboratory abnormalities will be analyzed be using the chi-square test or Fisher's Exact test. Any continuous measurement in physical examination and clinical laboratory will be analyzed by t-test or Wilcoxon rank test.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects are female
  • Subjects are 18 years of age or older at the time of consent
  • Subjects have a BMI between 17-40
  • Subjects must have signed informed consent form
  • Subjects have a preoperative diagnosis of uterine fibroids and plan to have a myomectomy completed surgically as part of their standard of care
  • Subjects must have a physical examination and compliance assessment

Exclusion Criteria:

  • Subjects whose BMI is outside the range of 17-40
  • Subjects participating in another clinical trial with a drug or device
  • Subjects who have participated in a clinical trial with a drug or device within 30 days prior to this study
  • Subjects with suspected or diagnosed pregnancy
  • Subjects with suspected intraabdominal infection
  • Subjects who are immunocompromised
  • Subjects diagnosed with cancer
  • Subjects treated with hemostatic agents (e.g. fibrin sealant, collagen, oxidized cellulose)
  • Subjects treated with adhesion prevention agents other than the Anti-Adhesion product (APP) (e.g. Intergel ® Adhesion Prevention Solution, Seprafilm ® Membrane)
  • Subjects taking anti-epileptic medication
  • Subjects who have been treated with Methotrexate or other chemotherapeutics agents
  • Subjects with an American Fertility Society score of Stage D at the time of myomectomy as determined by the surgeon
  • Positive viral serology screening results for hepatitis B surface antigen, antibodies to hepatitis C virus or human immunodeficiency
Layout table for additonal information
Responsible Party: Temple Therapeutics BV Identifier: NCT04250467    
Other Study ID Numbers: ADE002
First Posted: January 31, 2020    Key Record Dates
Last Update Posted: January 31, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Temple Therapeutics BV:
Additional relevant MeSH terms:
Layout table for MeSH terms
Tissue Adhesions
Pathologic Processes